List of works - Rene Bruno

A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics

scientific article published on 23 April 2018

A Model-Based Meta-analysis to Compare Efficacy and Tolerability of Tramadol and Tapentadol for the Treatment of Chronic Non-Malignant Pain.

scientific article

A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use

scientific article published on 20 November 2015

A modeling and simulation framework to support early clinical drug development decisions in oncology

scientific article published on 13 July 2010

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

scientific article published on 21 September 2019

Assessment of tumor growth inhibition metrics to predict overall survival

scientific article published on 01 August 2014

Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up

scientific article published on 05 July 2019

Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma.

scientific article published on 16 December 2016

Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study.

scientific article published on 26 April 2018

Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer.

scientific article published on 25 September 2010

Evaluation of tumor size response metrics to predict survival in oncology clinical trials.

scientific article published on 13 January 2014

Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.

scientific article published on 6 May 2013

Exploratory modeling and simulation to support development of motesanib in Asian patients with non-small cell lung cancer based on MONET1 study results

scientific article published on 17 January 2014

Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors.

scientific article published in December 2017

Model-Based Estimates of Tumor Growth Inhibition Metrics Are Time-Independent: A Reply to Mistry

scientific article published on 20 December 2016

Model-based drug development in oncology: what's next?

scientific article published in April 2013

Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

scientific article published on 27 July 2009

Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.

scientific article published on 28 July 2016

Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast.

scientific article

Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation

scientific article

Modeling and simulation of sexual activity daily diary data of patients with female sexual arousal disorder treated with sildenafil citrate (Viagra).

scientific article

Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients

scientific article

Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.

scientific article published on 25 September 2010

Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizum

scientific article published on 22 October 2013

Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models

scientific article published on 23 December 2019

Reply to U.R. Mansmann et al and M.-W. An et al

scientific article published on 28 October 2013

Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Response

scientific article published on 01 May 2020

Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer.

scientific article published on 26 December 2012

Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-A

scientific article published on 12 July 2016

Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer.

scientific article published on 8 April 2011

List of works by Rene Bruno

A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics

A Model-Based Meta-analysis to Compare Efficacy and Tolerability of Tramadol and Tapentadol for the Treatment of Chronic Non-Malignant Pain.

A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use

A modeling and simulation framework to support early clinical drug development decisions in oncology

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

Assessment of tumor growth inhibition metrics to predict overall survival

Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up

Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma.

Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study.

Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer.

Evaluation of tumor size response metrics to predict survival in oncology clinical trials.

Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.

Exploratory modeling and simulation to support development of motesanib in Asian patients with non-small cell lung cancer based on MONET1 study results

Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors.

Model-Based Estimates of Tumor Growth Inhibition Metrics Are Time-Independent: A Reply to Mistry

Model-based drug development in oncology: what's next?

Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.

Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast.

Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation

Modeling and simulation of sexual activity daily diary data of patients with female sexual arousal disorder treated with sildenafil citrate (Viagra).

Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients

Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.

Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizum

Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models

Reply to U.R. Mansmann et al and M.-W. An et al

Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Response

Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer.

Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-A

Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer.